Company logo

SGMO - Sangamo Therapeutics, Inc.

NASDAQ -> Healthcare -> Biotechnology
Brisbane, United States
Type: Equity

SGMO price evolution
SGMO
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Current assets
Cash $46.7 $58.01 $68.33 $79.74
Short term investments $35.8 $75.6 $76.27 $127.15
Net receivables $0.92 $1.15 $2.72 $7.03
Inventory
Total current assets $94.33 $147.58 $159.61 $227.09
Long term investments $39.04 $35.61
Property, plant & equipment $52.87 $55.65 $107.49 $108.57
Goodwill & intangible assets $51.55
Total noncurrent assets $70.99 $72.12 $165.47 $213.48
Total investments $35.8 $75.6 $115.31 $162.76
Total assets $165.32 $219.7 $325.07 $440.57
Current liabilities
Accounts payable $15.26 $15.46 $14.84 $19.92
Deferred revenue $1.49 $6.87 $11.39
Short long term debt
Total current liabilities $47.73 $48.48 $53.79 $57.84
Long term debt $33.52 $34.98 $36.37 $37.7
Total noncurrent liabilities $34.7 $36.29 $37.64 $47.12
Total debt $33.52 $34.98 $36.37 $37.7
Total liabilities $82.43 $84.78 $91.43 $104.96
Shareholders' equity
Retained earnings -$1406.38 -$1346.08 -$1241.92 -$1127.41
Other shareholder equity -$4.59 -$6.58 -$5.94 -$5.76
Total shareholder equity $82.89 $134.92 $233.64 $335.61
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $46.7 $101.94 $180.37 $132.83
Short term investments $35.8 $177.19 $197.68 $510.09
Net receivables $0.92 $4.47 $6.01 $5.22
Inventory
Total current assets $94.33 $300.33 $398.77 $659.67
Long term investments $29.84 $88.17 $50.53
Property, plant & equipment $52.87 $125.53 $124.7 $112.37
Goodwill & intangible assets $88.28 $93.46 $100.93
Total noncurrent assets $70.99 $262.18 $323.15 $278.88
Total investments $35.8 $207.03 $285.85 $560.62
Total assets $165.32 $562.51 $721.92 $938.55
Current liabilities
Accounts payable $15.26 $22.42 $9.76 $12.55
Deferred revenue $161.16 $252.49 $336.69
Short long term debt
Total current liabilities $47.73 $111.71 $127.89 $143.55
Long term debt $33.52 $38.99 $44.05 $38.4
Total noncurrent liabilities $34.7 $155.84 $218.69 $297.64
Total debt $33.52 $38.99 $44.05 $38.4
Total liabilities $82.43 $267.55 $346.58 $441.18
Shareholders' equity
Retained earnings -$1406.38 -$1148.55 -$956.27 -$777.98
Other shareholder equity -$4.59 -$8.4 -$3.99 $5.42
Total shareholder equity $82.89 $294.96 $375.34 $498.23
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Revenue
Total revenue $2.04 $9.4 $6.83 $157.96
Cost of revenue
Gross Profit $2.04 $9.4 $6.83 $157.96
Operating activities
Research & development $50.71 $57.09 $63.05 $63.22
Selling, general & administrative $13.1 $13.92 $16.01 $18.14
Total operating expenses $64.1 $115.81 $130.41 $139.92
Operating income -$62.06 -$106.41 -$123.57 $18.03
Income from continuing operations
EBIT -$60.57 -$102.89 -$120.77 $21.33
Income tax expense -$0.27 $1.27 -$6.26 $0.19
Interest expense
Net income
Net income -$60.3 -$104.16 -$114.51 $21.13
Income (for common shares) -$60.3 -$104.16 -$114.51 $21.13
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $176.23 $111.3 $110.7 $118.19
Cost of revenue
Gross Profit $176.23 $111.3 $110.7 $118.19
Operating activities
Research & development $234.06 $249.9 $230.82 $180.65
Selling, general & administrative $61.17 $62.68 $63.22 $67.1
Total operating expenses $450.24 $312.58 $294.04 $247.74
Operating income -$274 -$201.28 -$183.34 -$129.55
Income from continuing operations
EBIT -$262.9 -$191.85 -$177.98 -$120.65
Income tax expense -$5.07 $0.43 $0.31 $0.34
Interest expense
Net income
Net income -$257.83 -$192.28 -$178.29 -$121
Income (for common shares) -$257.83 -$192.28 -$178.29 -$121
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income -$60.3 -$104.16 -$114.51 $21.13
Operating activities
Depreciation $3.01 $7.42 $6.18 $5.58
Business acquisitions & disposals
Stock-based compensation $6.11 $6.19 $6.79 $8.28
Total cash flows from operations -$50.54 -$47.29 -$60.71 -$66.3
Investing activities
Capital expenditures -$2.67 -$2.74 -$5.54 -$10.2
Investments $40.38 $40.37 $48.01 $45.93
Total cash flows from investing $37.71 $37.63 $42.47 $35.73
Financing activities
Dividends paid
Sale and purchase of stock $0.22 $0 $6.71 $9.11
Net borrowings
Total cash flows from financing $0.17 -$0.1 $6.52 $8
Effect of exchange rate $1.35 -$0.55 $0.31 $0.37
Change in cash and equivalents -$11.31 -$10.32 -$11.41 -$22.2
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$257.83 -$192.28 -$178.29 -$121
Operating activities
Depreciation $22.19 $20.56 $17.64 $13.37
Business acquisitions & disposals -$0.12 -$0.7
Stock-based compensation $27.36 $31.65 $32.96 $25.71
Total cash flows from operations -$224.84 -$223.63 -$233.25 $169.88
Investing activities
Capital expenditures -$21.16 -$20.17 -$23.28 -$14.71
Investments $174.69 $79.46 $271.6 -$256.21
Total cash flows from investing $153.53 $59.28 $248.2 -$271.63
Financing activities
Dividends paid
Sale and purchase of stock $16.04 $86.76 $36.12 $153.87
Net borrowings
Total cash flows from financing $14.59 $84.66 $32.86 $153.1
Effect of exchange rate $1.48 $1.25 -$0.26 -$0.45
Change in cash and equivalents -$55.24 -$78.43 $47.54 $50.9
Fundamentals
Market cap N/A
Enterprise value N/A
Shares outstanding N/A
Revenue $176.23M
EBITDA -$240.71M
EBIT -$262.90M
Net Income -$257.83M
Revenue Q/Q -92.50%
Revenue Y/Y 58.34%
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA -89.63%
ROE -131.03%
Debt/Equity 0.99
Net debt/EBITDA -0.15
Current ratio 1.98
Quick ratio 1.98